Literature DB >> 25684967

Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.

Kenta Baba1, Akihiko Oshita1, Mohei Kohyama1, Satoshi Inoue1, Yuta Kuroo1, Takuro Yamaguchi1, Hiroyuki Nakamura1, Yoichi Sugiyama1, Tatsuya Tazaki1, Masaru Sasaki1, Yuji Imamura1, Yutaka Daimaru1, Hideki Ohdan1, Atsushi Nakamitsu1.   

Abstract

A 72-year-old woman with a sigmoid colon cancer and a synchronous colorectal liver metastasis (CRLM), which involved the right hepatic vein (RHV) and the inferior vena cava (IVC), was referred to our hospital. The metastatic lesion was diagnosed as initially unresectable because of its invasion into the confluence of the RHV and IVC. After she had undergone laparoscopic sigmoidectomy for the original tumor, she consequently had 3 courses of modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus cetuximab. Computed tomography revealed a partial response, and the confluence of the RHV and IVC got free from cancer invasion. After 3 additional courses of mFOLFOX6 plus cetuximab, preoperative percutaneous transhepatic portal vein embolization (PTPE) was performed to secure the future remnant liver volume. Finally, a right hemihepatectomy was performed. The postoperative course was uneventful. The patient was discharged from the hospital on postoperative day 13. She had neither local recurrence nor distant metastasis 18 mo after the last surgical intervention. This multidisciplinary strategy, consisting of conversion chemotherapy using FOLFOX plus cetuximab and PTPE, could contribute in facilitating curative hepatic resection for initially unresectable CRLM.

Entities:  

Keywords:  Cetuximab; Colorectal liver metastasis; Conversion chemotherapy; Initially unresectable; Percutaneous transhepatic portal vein embolization

Mesh:

Substances:

Year:  2015        PMID: 25684967      PMCID: PMC4323478          DOI: 10.3748/wjg.v21.i6.1982

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Standardized liver volumetry for portal vein embolization.

Authors:  Dario Ribero; Yun Shin Chun; Jean-Nicolas Vauthey
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

2.  Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

Authors:  Janja Ocvirk; Thomas Brodowicz; Fritz Wrba; Tudor E Ciuleanu; Galina Kurteva; Semir Beslija; Ivan Koza; Zsuzsanna Pápai; Diethelm Messinger; Ugur Yilmaz; Zsolt Faluhelyi; Suayib Yalcin; Demetris Papamichael; Miklós Wenczl; Zrinka Mrsic-Krmpotic; Einat Shacham-Shmueli; Damir Vrbanec; Regina Esser; Werner Scheithauer; Christoph C Zielinski
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

3.  Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie.

Authors:  D Jaeck; P Bachellier; M Guiguet; K Boudjema; J C Vaillant; P Balladur; B Nordlinger
Journal:  Br J Surg       Date:  1997-07       Impact factor: 6.939

4.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Authors:  G Folprecht; A Grothey; S Alberts; H-R Raab; C-H Köhne
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

Review 5.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

6.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

7.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

8.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.

Authors:  Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

10.  Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.

Authors:  V Catalano; F Loupakis; F Graziano; U Torresi; R Bisonni; D Mari; L Fornaro; A M Baldelli; P Giordani; D Rossi; P Alessandroni; L Giustini; R R Silva; A Falcone; S D'Emidio; S L Fedeli
Journal:  Br J Cancer       Date:  2009-03-03       Impact factor: 7.640

View more
  3 in total

1.  Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy.

Authors:  Hiroya Iida; Masaki Kaibori; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Masahiko Kinoshita; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  Mol Clin Oncol       Date:  2018-09-03

Review 2.  Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-.

Authors:  B Lintoiu-Ursut; A Tulin; S Constantinoiu
Journal:  J Med Life       Date:  2015

3.  SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.

Authors:  Yi-Jun Zhang; Jie-Wei Chen; Xiao-Sheng He; Hui-Zhong Zhang; Yi-Hong Ling; Jia-Huai Wen; Wei-Hao Deng; Peng Li; Jing-Ping Yun; Dan Xie; Mu-Yan Cai
Journal:  EBioMedicine       Date:  2018-01-09       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.